Cue Biopharma Reports Positive Phase 2 Results for CUE-221 in Chronic Hives

What happened

Cue Biopharma, Inc. (Nasdaq: CUE) announced positive topline results from a Phase 2 study of CUE-221 in chronic spontaneous urticaria, according to the company's press release and coverage of it carried by Stockhouse and Enid News. The company said the trial's primary endpoint and its key secondary endpoint were both met with high statistical significance, and that CUE-221 showed an overall favorable safety profile.

According to a summary of the release circulated by Stock Titan, 54% of patients on the highest dose of CUE-221 were hive-free at 12 weeks. The company said the results support advancement to a Phase 2b/3 registration study.

No SEC filing about the results is available yet, so this article relies on the company's announcement and the outlets that carried it.

What the company does

Cue Biopharma is a clinical-stage biopharmaceutical company, classified in SEC filings under pharmaceutical preparations. Clinical-stage means its drug candidates are still being tested in humans and it does not yet have a product approved for sale; its revenue, if any, is not from selling a medicine.

CUE-221 is the company's candidate for chronic spontaneous urticaria. A separate write-up published by Trader Times describes it as a dual antibody approach and says the lead candidate showed four to eight times the potency in IgE neutralization compared to Xolair. IgE is the antibody class that triggers allergic-type reactions; Xolair is an approved injectable biologic used in chronic hives and other conditions.

What this means

Chronic spontaneous urticaria is the clinical term for hives that appear without a known trigger and last six weeks or longer. A Phase 2 trial is the middle stage of clinical testing: its main job is to see whether a drug shows signs of working and is tolerable at the doses tested, before the much larger and more expensive Phase 3 trials that regulators weigh when deciding whether to approve a medicine.

A 'primary endpoint' is the single measurement chosen in advance as the main test of the trial; here the company says it was met with high statistical significance, meaning the result is unlikely to be explained by chance alone. 'Key secondary endpoint' refers to other pre-specified measurements, tested after the primary one, that support the main finding. 'Topline' results are the first summary of the data released by the sponsor, before the full dataset has been reviewed or published, and they can be revised as more analysis is done.

The hives-free figure is a count of patients, not a prediction about the drug's future. The next evident step, based on the company's own statement, is a Phase 2b/3 registration study, which is the type of trial designed to supply the evidence an approval decision would rest on. Whether or when such a trial starts, and what regulators eventually decide, is not established by this announcement.

Cue Biopharma's stock closed at $37.05 on the day of the announcement, down 2.09% from the prior close of $37.84, according to the price data. Price moves for small, thinly covered biotechs around trial readouts can be large and are not a verdict on the data.